David A Kalmbach1, Vivek Pillai2, J Todd Arnedt1, Christopher L Drake2. 1. Sleep and Circadian Research Laboratory, Departments of Psychiatry and Neurology, University of Michigan Medical School, Ann Arbor, MI. 2. Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, MI.
Abstract
STUDY OBJECTIVES: A primary focus of the National Institute of Mental Health's current strategic plan is "predicting" who is at risk for disease. As such, the current investigation examined the utility of premorbid sleep reactivity in identifying a specific and manageable population at elevated risk for future insomnia. METHODS: A community-based sample of adults (n = 2,892; 59.3% female; 47.9 ± 13.3 y old) with no lifetime history of insomnia or depression completed web-based surveys across three annual assessments. Participants reported parental history of insomnia, demographic characteristics, sleep reactivity on the Ford Insomnia in Response to Stress Test (FIRST), and insomnia symptoms. DSM-IV diagnostic criteria were used to determine insomnia classification. RESULTS: Baseline FIRST scores were used to predict incident insomnia at 1-y follow-up. Two clinically meaningful FIRST cutoff values were identified: FIRST ≥ 16 (sensitivity 77%; specificity 50%; odds ratio [OR] = 2.88, P < 0.001); and FIRST ≥ 18 (sensitivity 62%; specificity 67%; OR = 3.32, P < 0.001). Notably, both FIRST cut-points outperformed known maternal (OR = 1.49-1.59, P < 0.01) and paternal history (P = NS) in predicting insomnia onset, even after controlling for stress exposure and demographic characteristics. Of the incident cases, insomniacs with highly reactive sleep systems reported longer sleep onset latencies (FIRST ≥ 16: 65 min; FIRST ≥ 18: 68 min) than participants with nonreactive insomnia (FIRST < 16: 37 min; FIRST < 18: 44 min); these groups did not differ on any other sleep parameters. CONCLUSIONS: The current study established a cost- and time-effective strategy for identifying individuals at elevated risk for insomnia based on trait sleep reactivity. The FIRST accurately identifies a focused target population in which the psychobiological processes complicit in insomnia onset and progression can be better investigated, thus improving future preventive efforts.
STUDY OBJECTIVES: A primary focus of the National Institute of Mental Health's current strategic plan is "predicting" who is at risk for disease. As such, the current investigation examined the utility of premorbid sleep reactivity in identifying a specific and manageable population at elevated risk for future insomnia. METHODS: A community-based sample of adults (n = 2,892; 59.3% female; 47.9 ± 13.3 y old) with no lifetime history of insomnia or depression completed web-based surveys across three annual assessments. Participants reported parental history of insomnia, demographic characteristics, sleep reactivity on the Ford Insomnia in Response to Stress Test (FIRST), and insomnia symptoms. DSM-IV diagnostic criteria were used to determine insomnia classification. RESULTS: Baseline FIRST scores were used to predict incident insomnia at 1-y follow-up. Two clinically meaningful FIRST cutoff values were identified: FIRST ≥ 16 (sensitivity 77%; specificity 50%; odds ratio [OR] = 2.88, P < 0.001); and FIRST ≥ 18 (sensitivity 62%; specificity 67%; OR = 3.32, P < 0.001). Notably, both FIRST cut-points outperformed known maternal (OR = 1.49-1.59, P < 0.01) and paternal history (P = NS) in predicting insomnia onset, even after controlling for stress exposure and demographic characteristics. Of the incident cases, insomniacs with highly reactive sleep systems reported longer sleep onset latencies (FIRST ≥ 16: 65 min; FIRST ≥ 18: 68 min) than participants with nonreactive insomnia (FIRST < 16: 37 min; FIRST < 18: 44 min); these groups did not differ on any other sleep parameters. CONCLUSIONS: The current study established a cost- and time-effective strategy for identifying individuals at elevated risk for insomnia based on trait sleep reactivity. The FIRST accurately identifies a focused target population in which the psychobiological processes complicit in insomnia onset and progression can be better investigated, thus improving future preventive efforts.
Authors: Ravi Singareddy; Alexandros N Vgontzas; Julio Fernandez-Mendoza; Duanping Liao; Susan Calhoun; Michele L Shaffer; Edward O Bixler Journal: Sleep Med Date: 2012-03-17 Impact factor: 3.492
Authors: Julio Fernández-Mendoza; Antonio Vela-Bueno; Alexandros N Vgontzas; María José Ramos-Platón; Sara Olavarrieta-Bernardino; Edward O Bixler; Juan José De la Cruz-Troca Journal: Psychosom Med Date: 2010-04-05 Impact factor: 4.312
Authors: Julio Fernandez-Mendoza; Alexandros N Vgontzas; Edward O Bixler; Ravi Singareddy; Michele L Shaffer; Susan L Calhoun; Maria Karataraki; Antonio Vela-Bueno; Duanping Liao Journal: Sleep Date: 2012-05-01 Impact factor: 5.849
Authors: David A Kalmbach; Deirdre A Conroy; Hayley Falk; Vani Rao; Durga Roy; Matthew E Peters; Timothy E Van Meter; Frederick K Korley Journal: Sleep Date: 2018-10-01 Impact factor: 5.849
Authors: Jamie L Walker; Ivan Vargas; Christopher L Drake; Jason G Ellis; Alexandria Muench; Michael L Perlis Journal: Sleep Date: 2022-09-08 Impact factor: 6.313
Authors: Julio Fernandez-Mendoza; Kristina Puzino; Gregory Amatrudo; Elizaveta Bourchtein; Susan L Calhoun; David T Plante; Kate Kaplan Journal: J Clin Sleep Med Date: 2021-11-01 Impact factor: 4.062
Authors: Sixto E Sanchez; Lauren E Friedman; Marta B Rondon; Christopher L Drake; Michelle A Williams; Bizu Gelaye Journal: Sleep Med Date: 2020-02-17 Impact factor: 3.492